Equities

TuHURA Biosciences Inc

TuHURA Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.66
  • Today's Change0.31 / 9.25%
  • Shares traded11.70k
  • 1 Year change-69.07%
  • Beta0.7230
Data delayed at least 15 minutes, as of Nov 22 2024 16:32 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first line treatment for advanced Merkel cell carcinoma. In addition, the Company is leveraging its Delta receptor technology to develop novel bi-functional antibody drug conjugates (ADCs), targeting myeloid derived suppressor cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. Its IFx platform technology utilizes a proprietary plasmid DNA (pDNA) or messenger RNA (mRNA).

  • Revenue in USD (TTM)0.00
  • Net income in USD-7.54m
  • Incorporated2009
  • Employees1.00
  • Location
    TuHURA Biosciences Inc10500 University Center Dr., Suite 110TAMPA 33612United StatesUSA
  • Phone+1 (813) 875-6600
  • Fax+1 (604) 202-1384
  • Websitehttps://www.kintara.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
HURA:NAQ since
announced
Transaction
value
TuHURA Biosciences IncAnnounced03 Apr 202403 Apr 2024Announced4.27%--
Data delayed at least 15 minutes, as of Nov 22 2024 16:32 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
TriSalus Life Sciences Inc26.89m-58.65m129.85m112.00------4.83-1.68-1.680.8963-0.67060.88121.236.75240,098.20-181.70---265.24--87.10---206.19--2.00-26.4317.43--49.31---26.51------
Candel Therapeutics Inc0.00-52.20m132.67m42.00---------1.74-1.740.00-0.47490.00----0.00-145.85---227.04-------------30.42-----100.00---101.87------
Inhibikase Therapeutics Inc0.00-19.57m135.06m8.00---------2.72-2.720.00-0.07110.00----0.00-175.81-66.49-267.87-85.55-------1,139.14--------111.03-42.21-5.40------
Vaxart Inc16.76m-72.34m136.30m109.00--1.99--8.13-0.4182-0.41820.09280.30090.1231--8.18153,761.50-53.13-49.60-80.07-54.86-----431.61-1,398.00---189.180.0665--6,796.2612.1523.47--21.49--
Black Diamond Therapeutics Inc0.00-73.10m137.50m54.00--1.41-----1.36-1.360.001.720.00----0.00-47.12-40.29-53.28-43.29------------0.00------9.57---15.37--
Acumen Pharmaceuticals Inc0.00-81.67m138.78m51.00--0.639-----1.37-1.370.003.620.00----0.00-29.52---30.98--------------0.1202-------22.20------
TuHURA Biosciences Inc0.00-7.54m140.80m1.00--3.76-----12.70-12.700.001.070.00----0.00-267.72-224.08-62,658.33-346.74------------0.00------43.40------
PepGen Inc0.00-87.23m140.81m64.00--1.02-----2.98-2.980.004.220.00----0.00-52.16---58.79--------------0.00-------13.78------
CytoDyn Inc0.00-20.53m144.06m9.00---------0.0241-0.02410.00-0.06990.00----0.00-94.20-259.15-----------232,918.20--1.36--------35.70------
Sagimet Biosciences Inc0.00-37.52m144.88m10.00--0.8488-----1.29-1.290.005.300.00----0.00-27.02---27.94--------------0.00------8.60------
Achieve Life Sciences Inc0.00-32.94m148.70m22.00--4.75-----1.13-1.130.000.91240.00----0.00-91.19-86.31-107.21-119.59-----------22.540.2384------29.60---14.51--
Atossa Therapeutics Inc0.00-26.91m149.65m10.00--2.03-----0.2144-0.21440.000.58570.00----0.00-29.71-29.97-31.30-32.55------------0.00-------11.62---33.90--
Gossamer Bio Inc105.32m-71.65m150.60m135.00--2.78--1.43-0.3283-0.32830.45950.23890.3014----780,162.90-20.51-57.43-23.67-64.38-----68.03-----6.840.7847------21.61------
Data as of Nov 22 2024. Currency figures normalised to TuHURA Biosciences Inc's reporting currency: US Dollar USD

Institutional shareholders

1.98%Per cent of shares held by top holders
HolderShares% Held
Geode Capital Management LLCas of 30 Sep 2024444.42k1.06%
G1 Execution Services LLCas of 30 Sep 2024127.70k0.30%
UBS Securities LLCas of 30 Sep 2024103.77k0.25%
Nantahala Capital Management LLCas of 30 Sep 202479.77k0.19%
Clear Creek Financial Management LLCas of 30 Sep 202427.50k0.07%
Baader Bank AG (Investment Management)as of 30 Sep 202415.12k0.04%
The Vanguard Group, Inc.as of 30 Sep 202412.46k0.03%
SSgA Funds Management, Inc.as of 30 Sep 202410.72k0.03%
Tower Research Capital LLCas of 30 Sep 20249.86k0.02%
Wells Fargo Advisors Financial Network LLCas of 30 Sep 20241.62k0.00%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.